EW stock: buy or sell?
August 19th, 2019
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally.
Should I buy EW stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Having a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
These 2 buy setups work for Edwards Lifesciences stock right now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Edwards Lifesciences stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 15 ratings published for EW stock in the last month. The general sentiment of these ratings is bullish for EW stock, with 12 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-7-24||Wells Fargo & Co||n/a||Outperform|
|2019-7-24||JPMorgan Chase & Co.||n/a||Neutral|
|2019-7-24||Jefferies Financial Group||n/a||Buy|
|2019-7-24||Credit Suisse Group||n/a||Outperform|
|2019-7-24||BMO Capital Markets||n/a||Outperform|
|2019-7-24||Bank of America||Buy||Buy|
|2019-4-24||Jefferies Financial Group||n/a||Buy|
EW stock analysis
Edwards Lifesciences inched 1.44% today and peaked a new all time high at $223.95.
Edwards Lifesciences shares inched 1.44% today and peaked a new all time high at $223.95. EW shows a sign of strength in the short-term after finally breaking out above $219.70 on Tuesday and marking a new rising bottom. Since last Jul 11th when SMA50d and SMA100d crossed up, EW price gained $31.32 per share (16.38%). Since last June when EW stock price broke up the SMA100d line, it gained $48.46 (27.84%).
Edwards Lifesciences topped new all time highs again this week, marking to $223.95. Shares ended at $222.50 and raised 1.44% during the week. With this, it's been 5 climbing weeks in a row, soaring a 14.71%. Late July EW boosted an astounding 8.70% in just one week.
Edwards Lifesciences stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, EW might consolidate in a flat-base, waiting to break out over or down under . Late December 2018 EW price bounced up over the SMA of 40 weeks that acted as support stopping new slides.
EW stock price history
EW IPO was on March 27th, 2000 at $3.81 per share1. Since then, EW stock grew a 5,739.90%, with an average of 302.10% per year. If you had invested right after EW's IPO a $1,000 in EW stock in 2000, it would worth $57,399.00 today.
1: Adjusted price after possible price splits or reverse-splits.
EW stock historical price chart
EW stock reached all-time highs today with a price of $223.95.
EW stock price target is $221.60Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' EW stock price predictions in the hope that they will be met as they may be wrong and not met. We found 14 price targets for Edwards Lifesciences stock published in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-7-24||Wells Fargo & Co||Reiterates||$207.00||$220.00||6.3%|
|2019-7-24||Raymond James||Raises Target||$200.00||$232.00||16%|
|2019-7-24||Morgan Stanley||Raises Target||$210.00||$228.00||8.6%|
|2019-7-24||JPMorgan Chase & Co.||Raises Target||$190.00||$225.00||18.4%|
|2019-7-24||Jefferies Financial Group||Reiterates||$210.00||$245.00||16.7%|
|2019-7-24||Credit Suisse Group||Reiterates||$221.00||$226.00||2.3%|
|2019-7-24||BMO Capital Markets||Reiterates||$204.00||$224.00||9.8%|
|2019-7-24||Bank of America||Reiterates||$215.00||$225.00||4.7%|
|2019-7-16||Morgan Stanley||Raises Target||$197.00||$210.00||6.6%|
|2019-4-24||Raymond James||Lowers Target||$210.00||$200.00||-4.8%|
|2019-4-24||Jefferies Financial Group||Raises Target||$195.00||$210.00||7.7%|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter presenting its last earnings report on April, Edwards Lifesciences rocketed an astounding 24.81%. Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw an excellent increase of 8.37% to $3,722.80 million dollars. Instead, its profit margin (compared to revenues) gained to 19.40%, that is $722.20 million. To have an up to date view of the financial situation of Edwards Lifesciences, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2019-Q1 that can be compared to 2018 fiscal year results. Annual Edwards Lifesciences TTM sales up to March 2019 were $3,821.00 and earnings were $765.30 million dollars. If we compare this TTM figures with the last reported annuality, we can esteem Edwards Lifesciences business evolution since December 2018: Annual turnover up to March, compared to lastest yearly report, raised a slightly good 2.64%. Regarding profit margin, Edwards Lifesciences remained steady 0.63% to 19.40%
|2013||$2,050 M||-||$392 M19.1%||-|
|2014||$2,323 M||13.31%||$811 M34.9%||107.07%|
|2015||$2,494 M||7.35%||$495 M19.8%||-38.98%|
|2016||$2,964 M||18.85%||$570 M19.2%||15.07%|
|2017||$3,435 M||15.91%||$584 M17.0%||2.48%|
|2018||$3,723 M||8.37%||$722 M19.4%||23.75%|
|TTM||$3,821 M||2.64%||$765 M20.0%||5.97%|
Quarterly financial resultsEdwards Lifesciences reported $993.00 M in revenues for 2019-Q1, a 1.56% up compared to previous quarter. Reported quarter income marked $249.70 M with a profit margin of 25.15%. Profit margin skyrocketed a 24.43% compared to previous quarter when profit margin was 0.72%. When comparing turnover to same quarter last year, Edwards Lifesciences sales marked a superb increase and boosted a 10.97%. Looking back to recent quarterly results, Edwards Lifesciences posted 2 negative quarters in a row.
|2017-Q2||$842 M||-||$186 M22.1%||-|
|2017-Q3||$822 M||-2.41%||$170 M20.7%||-8.60%|
|2017-Q4||$889 M||8.16%||$-3 M-0.3%||-101.65%|
|2018-Q1||$895 M||0.71%||$207 M23.1%||-7,478.57%|
|2018-Q2||$944 M||5.46%||$283 M30.0%||36.83%|
|2018-Q3||$907 M||-3.93%||$226 M24.9%||-20.09%|
|2018-Q4||$978 M||7.84%||$7 M0.7%||-96.90%|
|2019-Q1||$993 M||1.56%||$250 M25.1%||3,467.14%|
Edwards Lifesciences ownershipWhen you are planning to invest in shares of a company, it's worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Edwards Lifesciences, 3.94% of all outstanding shares are owned by its staff.
In case of Edwards Lifesciences stock, 0.00% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for EW stock account 0.00%, no big difference from last month.
For a better context understanding, the next table shows ownership data compared to other related companies:
|Market cap||$46.3 B||$59.4 B||$985.4 M||$3.4 B||$620.0 M|
|Total shares||208.1 M||1,390.0 M||37.3 M||20.6 M||19.7 M|
|Float shares||206.6 M||1,390.0 M||35.9 M||19.2 M||15.9 M|
|- Institutional holdings (%)||0.0%||93.4%||72.1%||93.5%||77.8%|
|- Insider holdings (%)||3.9%||0.2%||3.8%||7.1%||18.5%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Monday, August 19th, 2019|
|Day range||$220.24 - $223.95|
|Average true range||$5.11|
|50d mov avg||$199.05|
|100d mov avg||$189.45|
|200d mov avg||$176.63|
Edwards Lifesciences performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We chose Boston Scientific, CryoLife, ICU Medical, LeMaitre Vascular, Medtronic and Merit Medical Systems as the bechmarking frame for Edwards Lifesciences stock.
|MMSIMerit Medical Sys...||-34.09%||-39.30%||-36.13%|
Edwards Lifesciences competitorsWe picked a few stocks to conform a list of Edwards Lifesciences competitors to check if you are interested in investing in EW:
- Boston Scientific (BSX)
- CryoLife (CRY)
- ICU Medical (ICUI)
- LeMaitre Vascular (LMAT)
- Medtronic (MDT)
- Merit Medical Systems (MMSI)
Latest EW stock news
- Seeking AlphaEdwards Lifesciences Beats, Raises And Surges: AnalysisJuly 24, 2019
- Seeking AlphaEdwards Lifesciences: A Med-Tech Stock Staying Strong For A ReasonMay 15, 2019
- Seeking AlphaEdwards Lifesciences: Assessing The Next MovesMay 1, 2019
- Seeking AlphaEdwards Lifesciences: It's Expensive, But It's Recession-ProofFebruary 20, 2019
- Seeking AlphaEdwards Lifesciences: Good For The Heart And Your PortfolioAugust 17, 2018